Physician profile
William Michael Hall
NPI 1134199961
$5,949.95
in general payments reported to CMS, 2019-2025
48 companies · $358 in 2025
The $358 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,378 · 2020: $909 · 2021: $362 · 2022: $434 · 2023: $922 · 2024: $588 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,867.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $581.51 | 2019-2025 | Spravato, Xarelto |
| Amgen INC. | $550.92 | 2019-2024 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $495.05 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Abbvie INC. | $465.53 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $403.92 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $279.26 | 2019-2025 | Arexvy |
| Novo Nordisk INC | $236.28 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $228.14 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $215.06 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $212.35 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $207.93 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $184.93 | 2023 | Verquvo |
| Otsuka America Pharmaceutical, INC. | $178.00 | 2019-2023 | Nuedexta, Rexulti |
| Amarin Pharma, INC. | $171.47 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $149.24 | 2021 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.